The immunohistochemical data suggest no effect (RR 0.92; c.i. 0.61–1.39), whereas the more limited data using analysis of mutations suggest that abnormal p53 may significantly increase the risk of the development of metastatic disease (RR 1.67; c.i. 1.21–2.30). This evidence concerns the gene TP53 and metastatic neoplasm.